Cargando…

Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies

This report presents a case of a neurofascin-155 (NF155)+ autoimmune nodopathy (AN) patient who exhibited resistance to conventional treatments but responded positively to telitacicept therapy. Telitacicept, a dual inhibitor of B lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yijun, Chen, Si, Yang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642300/
https://www.ncbi.nlm.nih.gov/pubmed/37965304
http://dx.doi.org/10.3389/fimmu.2023.1279808
_version_ 1785146938931281920
author Ren, Yijun
Chen, Si
Yang, Huan
author_facet Ren, Yijun
Chen, Si
Yang, Huan
author_sort Ren, Yijun
collection PubMed
description This report presents a case of a neurofascin-155 (NF155)+ autoimmune nodopathy (AN) patient who exhibited resistance to conventional treatments but responded positively to telitacicept therapy. Telitacicept, a dual inhibitor of B lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), suppressed the development and survival of plasma cells and mature B cells. The patient’s unique clinical features were consistent with NF155+ AN, showing limited response to standard treatments like rituximab and a recurrent significant increase in anti-NF155 antibody titers. Administering telitacicept (160mg, ih) led to an improvement in clinical symptoms, inflammatory neuropathy cause and treatment (INCAT) scale and inflammatory Rasch-built overall disability scale (I-RODS), and stabilized anti-NF155 antibody levels without a rebound. This case demonstrates telitacicept as a potential novel therapy for NF155+ AN, particularly when conventional treatments fail. Further investigation into its safety, efficacy, dosage, and treatment cycle in NF155+ AN is warranted.
format Online
Article
Text
id pubmed-10642300
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106423002023-11-14 Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies Ren, Yijun Chen, Si Yang, Huan Front Immunol Immunology This report presents a case of a neurofascin-155 (NF155)+ autoimmune nodopathy (AN) patient who exhibited resistance to conventional treatments but responded positively to telitacicept therapy. Telitacicept, a dual inhibitor of B lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), suppressed the development and survival of plasma cells and mature B cells. The patient’s unique clinical features were consistent with NF155+ AN, showing limited response to standard treatments like rituximab and a recurrent significant increase in anti-NF155 antibody titers. Administering telitacicept (160mg, ih) led to an improvement in clinical symptoms, inflammatory neuropathy cause and treatment (INCAT) scale and inflammatory Rasch-built overall disability scale (I-RODS), and stabilized anti-NF155 antibody levels without a rebound. This case demonstrates telitacicept as a potential novel therapy for NF155+ AN, particularly when conventional treatments fail. Further investigation into its safety, efficacy, dosage, and treatment cycle in NF155+ AN is warranted. Frontiers Media S.A. 2023-10-30 /pmc/articles/PMC10642300/ /pubmed/37965304 http://dx.doi.org/10.3389/fimmu.2023.1279808 Text en Copyright © 2023 Ren, Chen and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ren, Yijun
Chen, Si
Yang, Huan
Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies
title Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies
title_full Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies
title_fullStr Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies
title_full_unstemmed Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies
title_short Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies
title_sort case report: telitacicept in treating a patient with nf155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-nf155 antibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642300/
https://www.ncbi.nlm.nih.gov/pubmed/37965304
http://dx.doi.org/10.3389/fimmu.2023.1279808
work_keys_str_mv AT renyijun casereporttelitaciceptintreatingapatientwithnf155autoimmunenodopathyasuccessfulattempttomanagerecurrentelevatedseroantinf155antibodies
AT chensi casereporttelitaciceptintreatingapatientwithnf155autoimmunenodopathyasuccessfulattempttomanagerecurrentelevatedseroantinf155antibodies
AT yanghuan casereporttelitaciceptintreatingapatientwithnf155autoimmunenodopathyasuccessfulattempttomanagerecurrentelevatedseroantinf155antibodies